BiotechTube
Model Medicines

Model Medicines

San Diego, United States· Est.
modelmedicines.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.

VirologyOncology

Technology Platform

GALILEO™, an AI/ML platform for drug discovery featuring ultra-large virtual screening and agentic AI. Includes AmesNet™, a best-in-class deep learning model for Ames mutagenicity prediction.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The broad-spectrum, pan-antiviral approach for MDL-001 addresses a significant unmet need for therapeutics effective against multiple virus families and variants, potentially capturing value across several large infectious disease markets.
Success in advancing its AI-discovered oncology candidates could demonstrate platform utility in a complex therapeutic area with high willingness-to-pay.

Risk Factors

The high-risk transition from AI-predicted, cell-validated compounds to safe and effective human drugs remains unproven.
As a pre-revenue company, it is dependent on volatile capital markets for funding to reach costly clinical milestones.
Intense competition in both AI drug discovery and the antiviral/therapeutic oncology spaces threatens market positioning.

Competitive Landscape

Model Medicines competes in the crowded AI-driven drug discovery sector against companies like Recursion, Exscientia, and Insilico Medicine, as well as internal efforts at large pharma. Its specific focus on a pan-antiviral places it against established antiviral developers and other biotechs pursuing broad-spectrum approaches. Differentiators include its claimed best-in-class Ames mutagenicity prediction and its strategy of fully owning its pipeline assets.

More companies in AI / Machine Learning →More companies in United States →